

FOR IMMEDIATE RELEASE

Contact:

Mr. Tom Cannon, VP/General Manager, Tissue Genesis, Inc.
(808) 539-9331

TCannon@TissueGenesis.com

TGI Co-Founder Accepts Prestigious Appointments

Honolulu, HI May 29, 2003-- Tissue Genesis Incorporated (TGI) announces the appointment of co-founder William P. Wiesmann MD to two external advisory positions-- the Chairman of the Scientific Advisory Board of the National Tissue Engineering Center (NTEC), and the University of Southern California (USC) Board of Councilors.

Commencing in 2002, The National Tissue Engineering Center is a federally funded initiative to support defense-related biotechnology research and development. NTEC directs multi-disciplinary civilian and military research teams to transfer innovative medical technologies to clinical practice. The NTEC is focusing on three general areas: wound healing, cardiothoracic and vascular tissue engineering, and musculoskeletal tissue engineering.

"During these early stages of work, the NTEC needs to pursue innovative technology as well as address the needs of our constituency," said NTEC Executive Director Alan Russell. "I believe Dr. Wiesmann is uniquely qualified to work with us in this effort."

"We are very pleased that Dr. Wiesmann has joined the School's Board of Councilors," said Max Nikias, USC Dean of Engineering. "The School will substantially profit from his perspective and experience as a prominent member of the biomedical engineering industry."

USC's School of Engineering is a leader in university-based research. The USC graduate program in engineering is ranked eighth in the nation by U. S. News and World Report. USC is home to the Mann Institute for Biomedical Engineering, a \$100-million center dedicated to the development of medical devices to improve human health and well-being.

Wiesmann stated, "I am honored to be selected for these appointments and I look forward to working with such impressive institutions. I have been tremendously impressed with their visions and scope of research, many of which are complementary to our goals at TGI."

Dr. Wiesmann has extensive experience in medical program development, management, and biomedical scientific research. Dr. Wiesmann was previously the Research Area Director for Combat Casualty Care at the U.S. Army Medical Research and Materiel Command at Ft. Detrick, Maryland, where he managed the

entire US Army Combat Casualty Care intramural and extramural research programs. Following his military retirement in 1997, Dr. Wiesmann founded several small biotechnology companies focusing on the development of non-invasive sensors, automated diagnostic devices, and tissue engineering capabilities. He holds an adjunct faculty appointment in Bioengineering at Clemson University and serves on the Board of Trustees of Harvey Mudd College in Claremont, Calif.

TGI is a Hawaii based vascular biology company developing biocompatible tissue replacement products to improve survival rates from trauma injuries, cardiovascular diseases, cancer and metabolic diseases and tissue engineering equipment & hardware support devices. TGI is currently developing controlled bioreactor technology for optimizing cell and tissue growth, connective tissue constructs and autologous vascular grafts based on an elastin matrix.